Arctigenin Attenuates Breast Cancer Progression through Decreasing GM-CSF/TSLP/STAT3/β-Catenin Signaling

Shi, Hui; Zhao, Luping; Guo, Xinlin; Fang, Runping; Zhang, Hui; Dong, Guanjun; Fu, Jia; Yan, Fenglian; Zhang, Junfeng; Ning, Zhaochen; Ma, Qun; Li, Zhihua; Li, Chunxia; Dai, Jun; Si, Chuanping; Xiong, Huabao

doi:10.3390/ijms21176357

Cited by 16 publications

(10 citation statements)

References 59 publications

(66 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…End1/E6E7, SiHa and HeLa were incubated with 0, 1.25, 2.5, 5, 10, 20, 40 μM ARG for 24 h [ 16 ] to determine the toxic effect of ARG on cells. Among them, 0 μM ARG designated that cells were treated with phosphate buffer saline (PBS, C0221A, Beyotime).…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Arctigenin hinders the invasion and metastasis of cervical cancer cells via the FAK/paxillin pathway

Liao

Liu

et al. 2023

Heliyon

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

“…More importantly, ARG has been identified as an anti-tumor agent [ 15 ]. ARG restrains proliferation, invasion and stemness of breast cancer cells [ 16 ]. An inhibitory effect of ARG is reported on cell growth, mobility and epithelial-mesenchymal transition (EMT) with the enhanced apoptosis in cholangiocarcinoma [ 17 ].…”

Section: Introductionmentioning

confidence: 99%

Arctigenin hinders the invasion and metastasis of cervical cancer cells via the FAK/paxillin pathway

Liao

Liu

et al. 2023

Heliyon

View full text Add to dashboard Cite

“…In those risk predictors, the level of TSLP expression was correlated with breast cancer growth and metastasis (Kuan and Ziegler, 2018;Shi et al, 2020). PSME2, IL18 and NPR3 have been reported to have a close correlation with the proliferation, invasion, and migration of various tumors including breast cancer (Li et al, 2016a;Gu et al, 2018;Ramdas et al, 2019;Wang et al, 2021).…”

Section: Runx3 Could Target and Regulate Ulbp2 And Trdv1mentioning

confidence: 99%

RUNX regulated immune-associated genes predicts prognosis in breast cancer

Sun

et al. 2022

Front. Genet.

View full text Add to dashboard Cite

Background: Breast cancer is the most common malignant tumor in women. RUNX family has been involved in the regulation of different carcinogenic processes and signaling pathways with cancer, which is closely related to immunity and prognosis of various tumors, and also plays an important role in the development and prognosis of breast cancer.Methods: We discovered the expression of RUNX family through GEPIA Dataset and then evaluated the relationship between RUNX family and immune-related genes and the prognosis of breast cancer through analyzing TCGA database. A prognostic model was established and verified via cox proportional hazards regression model using R packages. We evaluated the accuracy of the prognostic model by Kaplan-Meier curves and receiver operating characteristic (ROC) curves. Additionally, we obtained the relationship between the RUNX family and immune infiltration by TIMER database. Finally, the dual luciferase reporter assay was used to verify the regulation of RUNX3 on potential target genes ULBP2 and TRDV1, and the effects of ULBP2 and TRDV1 on the growth of breast cancer cells were explored by CCK-8, colony formation and wound healing assays.Results: We screened out RUNX family-regulated immune-related genes associated with the prognosis of breast cancer. These predictors included PSME2, ULBP2, IL-18, TSLP, NPR3, TRDV1. Then a prognosis-related risk score model was built using the independent risk factors to provide a clinically appropriate method predicting the overall survival (OS) probability of the patients with breast cancer. In addition, a further research was made on the functions of high risk immune gene ULBP2 and low risk immune gene TRDV1 which regulated by RUNX3, the results showed that down-regulation of ULBP2 suppressed breast cancer cell proliferation and TRDV1 had the opposite functions. The prognostic model we constructed could promote the development of prognostic, and was associated with lower immune infiltration.Conclusion: The expression of RUNX family was closely related to the prognosis of breast cancer. At the same time, RUNX family could modulate the functions of immune-related genes, and affect the development and prognosis of breast cancer. These immune-related genes regulated by RUNX family could be promising prognostic biomarkers and therapeutic targets in breast cancer.

show abstract

“…This compound stimulates apoptosis and decreases viability of tumor cells. It affects various molecular pathways such as STAT3 and β‐catenin in impairing tumor progression (Shi et al 2020; Sun et al 2018a, b; Janthamala et al 2021; Luo et al 2021a, b, c). Acidic tumor microenvironment induces drug resistance in prostate cancer.…”

Section: Pi3k/akt In Therapy Resistancementioning

confidence: 99%

Targeting PI3K/Akt signaling in prostate cancer therapy

Hashemi

Taheriazam

Daneii

et al. 2022

J. Cell Commun. Signal.

View full text Add to dashboard Cite

Urological cancers have obtained much attention in recent years due to their mortality and morbidity. The most common and malignant tumor of urological cancers is prostate cancer that imposes high socioeconomic costs on public life and androgen‐deprivation therapy, surgery, and combination of chemotherapy and radiotherapy are employed in its treatment. PI3K/Akt signaling is an oncogenic pathway responsible for migration, proliferation and drug resistance in various cancers. In the present review, the role of PI3K/Akt signaling in prostate cancer progression is highlighted. The activation of PI3K/Akt signaling occurs in prostate cancer, while PTEN as inhibitor of PI3K/Akt shows down‐regulation. Stimulation of PI3K/Akt signaling promotes survival of prostate tumor cells and prevents apoptosis. The cell cycle progression and proliferation rate of prostate tumor cells increase by PI3K/Akt signaling induction. PI3K/Akt signaling stimulates EMT and enhances metastasis of prostate tumor cells. Silencing PI3K/Akt signaling impairs growth and metastasis of prostate tumor cells. Activation of PI3K/Akt signaling mediates drug resistance and reduces radio‐sensitivity of prostate tumor cells. Anti‐tumor compounds suppress PI3K/Akt signaling in impairing prostate tumor progression. Furthermore, upstream regulators such as miRNAs, lncRNAs and circRNAs regulate PI3K/Akt signaling and it has clinical implications for prostate cancer patients.

show abstract

Arctigenin Attenuates Breast Cancer Progression through Decreasing GM-CSF/TSLP/STAT3/β-Catenin Signaling

Cited by 16 publications

References 59 publications

Arctigenin hinders the invasion and metastasis of cervical cancer cells via the FAK/paxillin pathway

Arctigenin hinders the invasion and metastasis of cervical cancer cells via the FAK/paxillin pathway

RUNX regulated immune-associated genes predicts prognosis in breast cancer

Targeting PI3K/Akt signaling in prostate cancer therapy

Contact Info

Product

Resources

About